Where does Acosta Medical Group rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Acosta Medical Group ranks #44,380 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Acosta Medical Group hold?

Acosta Medical Group holds 5 US utility patents granted between 2020 and 2023, spanning 3 technology areas.

What is Acosta Medical Group's Innovation Score?

Acosta Medical Group has an Innovation Score of 43.4 out of 100 (top 28% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

Is Acosta Medical Group's patent grant rate increasing or decreasing?

Insufficient historical data is available to calculate a velocity trend for Acosta Medical Group.

What does claim depth mean for Acosta Medical Group's patents?

Acosta Medical Group's patents average 18.4 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Acosta Medical Group patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Acosta Medical Group

Q: What technology areas does Acosta Medical Group focus on?

Acosta Medical Group's top technology area is A61F (Filters Implantable Into Blood VESSELS; PROSTHESES; Devices Providing Patency TO, OR Preventing Collapsing OF, Tubular Structures OF THE Body, e.g. STENTS; Orthopaedic, Nursing OR Contraceptive DEVICES; FOMENTATION; Treatment OR Protection OF Eyes OR EARS; Bandages, Dressings OR Absorbent PADS; Firs) with 5 patents, ranking #1,191 of 3,082 assignees active in that subclass. Grants appear in 3 CPC subclasses total.

USPTO PatentsView assignee record - 5 granted patents across 3 technology areas, recorded in grant years 2020–2023. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61F (Filters Implantable Into Blood VESSELS; PROSTHESES; Devices Providing Patency TO, OR Preventing Collapsing OF, Tubular Structures OF THE Body, e.g. STENTS; Orthopaedic, Nursing OR Contraceptive Device).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Acosta ranks #44,380 of 49,997 tracked US assignees by granted-patent volume, with 5 patents across 3 technology areas.

#44,380
of 49,997 US assignees by volume: Top 28%
by Innovation Score (43.4/100): 18.4
avg claims per patent

USPTO PatentsView assignee plate

Corpus R44380 · US Corporation #44,380 · 5 grants

GRANTS-MICRO · LOWER-Q · PHOTO-FINISH · CPC-NARROW · INNOV-PAR · CLAIMS-RICH · TYPE-USCORP · SPAN-YRS · BOOK-RICH

GRANTS-MICRO 5 grants
LOWER-Q #44,380/49,997
PHOTO-FINISH Acesion Pharma APS
CPC-NARROW A61F · 3 areas
INNOV-PAR 43.4/100
CLAIMS-RICH 18.4 claims/avg
TYPE-USCORP US Corporation
SPAN-YRS 2020–2023 · 4y
BOOK-RICH 9/10 fields

Nearest grant-volume peer: Acesion Pharma APS (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Acosta’s 43.4 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 6.2 pts (14%) Velocity 20.0 pts (46%) Breadth 6.1 pts (14%) Claim depth 11.0 pts (25%)

Qualcomm Incorporated · highest

85
Acosta Medical Group · this assignee

43
3D Lighting… · lowest

7

What this shows Acosta's Innovation Score is 43.4/100 (top 28% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Acosta?

Each dot is one of Acosta’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Acosta’s own 18.4 claims/patent is at or below the 18.4 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.

Acosta vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Acosta's grants concentrate

Acosta Medical Group is a focused PatentsView assignee: 3 CPC subclasses with 100% of grants classified under A61F (Filters Implantable Into Blood VESSELS; PROSTHESES; Devices Providing Patency TO, OR Preventing Collapsing OF, Tubular Structures OF THE Body, e.g. STENTS; Orthopaedic, Nursing OR Contraceptive Device). Peak complete grant year is 2022 (2 grants) versus a trough of 1 in 2020. By volume, Acosta sits between Acesion Pharma APS and ACP Ltd..

Acosta's three-year grant acceleration

Acosta Medical Group shows 4 grants in 2022–2024 against only 1 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Acesion Pharma APS

5
ACH Food Companies

5
Achernartek

5
ACM Research

5
Acousort AB

5
Acousticeye

5
Acouva

5
ACP

5
Acosta Medical Gr… ◀

5

What this shows Acosta holds 5 patents at rank #44,372, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Acosta

By rank, the assignees closest to #44,372 in granted patent volume.

Leaders in A61F (Filters Implantable Into Blood Vessels)

Other assignees with the most granted patents in Acosta's primary technology class.

Acosta's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

43 Top 28% higher than 72% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2020–2023

Grants by year

Teal-shaded recent years (2020–present) versus the 2020–2019 baseline. Full figures in the table below.

View data table

Acosta Medical Group patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2020	1	20.0%
2022	2	40.0%
2023	2	40.0%

Which technologies does Acosta Medical Group patent most?

A61F - Filters Implantable Into Blood VESSELS; PROSTHESES; Devices Providing Patency TO, OR Preventing Collapsing OF, Tubular Structures OF THE Body, e.g. STENTS; Orthopaedic, Nursing OR Contraceptive DEVICES; FOMENTATION; Treatment OR Protection OF Eyes OR EARS; Bandages, Dressings OR Absorbent PADS; Firs 5

A61B - DIAGNOSIS; SURGERY; Identification 3

A61M - Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor 2

Top 3 of 3 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Acosta Medical Group's patent record in context - here's where to go next.

Acosta Medical Group's lead technology class is A61F (Filters Implantable Into Blood VESSELS; PROSTHESES; Devices Providing Patency TO, OR Preventing Collapsing OF, Tubular Structures OF THE Body, e.g. STENTS; Orthopaedic, Nursing OR Contraceptive Device), 100% of its portfolio - see every assignee active in that class. Explore A61F
Ranked #44,380 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Acosta Medical Group against Acesion Pharma APS, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 43.4/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent , US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.